Quick Links

 Selected Publications

Juhasz A., Frankel P., Cheng C., Rivera H., Vishwanath R., Chiu A., Margolin K., Yen Y., Newman E.M., Synold T., Wilczynski S., Lenz H.J., Gandara D., Albain K.S., Longmate J., and Doroshow J.H. Quantification of Chemotherapeutic Target Gene mRNA Expression in Human Breast Cancer Biopsies: Comparison of Real-time Reverse Transcription-PCR vs. Relative Quantification Reverse Transcription-PCR Utilizing DNA Sequencer Analysis of PCR Products. J. Clin. Lab. Anal. 17: 184-194, 2003.

Morgan R.J. Jr., Newman E.M., Sowers L., Scanlon K., Harrison J., Akman S., Leong L., Margolin K., Niland J., Raschko J., Somlo G., Carroll M., Chow W., Tetef M., Hamasaki V., Yen Y., and Doroshow J.H. Phase I Study of Cisdiamminedichloroplatinum in Combination with Azidothymidine in the Treatment of Patients with Advanced Malignancies. Cancer Chemother. Pharmacol. 51: 459-464, 2003.

Aparicio A., Eads C.A., Leong L.A., Laird P.W., Newman E.M., Synold T.W., Baker S.D., Zhao M., and Weber J.S. Phase I Trial of Continuous Infusion 5-aza-2'-deoxycytidine. Cancer Chemother. Pharmacol. 51: 231-239, 2003.

Yen Y., Chow W., Leong L., Margolin K., Morgan R., Raschko J., Shibata S., Somlo G., Twardowski P., Frankel P., Longmate J., Synold T., Newman E.M., Lenz H.J., Gandara D., and Doroshow J.H. Phase I Pharmacodynamic Study of Time and Sequence Dependency of Hydroxyurea in Combination with Gemcitabine: A California Cancer Consortium Trial. Cancer Chemother. Pharmacol. 50: 353-359, 2002.

Tetef M.L., Margolin K.A., Doroshow J.H., Akman S., Leong L.A., Morgan R.J. Jr., Raschko J.W., Slatkin N., Somlo G., Longmate J.A., Carroll M.I., and Newman E.M. Pharmacokinetics and Toxicity of High-dose Intravenous Methotrexate in the Treatment of Leptomeningeal Carcinomatosis. Cancer Chemother. Pharmacol. 46: 19-26, 2000.

Synold T.W., Newman E.M., Carroll M., Muggia F.M., Groshen S., Johnson K., and Doroshow J.H. Cellular but not Plasma Pharmacokinetics of Lometrexol Correlate with the Occurrence of Cumulative Hematological Toxicity. Clin. Cancer. Res. 4: 2349-2355, 1998.


This is a partial list. Full publications list available upon request.  Information on this page may be self-reported. Last updated: 07/08.

 Search

Go!
Advanced Search Options
News & Publications Search
NCI CCC LogoCity of Hope is one of 40 Comprehensive Cancer Centers, the highest designation bestowed by the National Cancer Institute and a recognition of excellence in cancer treatment, research, prevention and education.
City of Hope strongly supports and values the uniqueness of all individuals and promotes a work environment where diversity is embraced.
NCI CCC LogoThe National Comprehensive Cancer Network®
(NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HON code of the Healthcare on the Net Foundation.